Search Results - "Flinn, Ian W."

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial by Locke, Frederick L, Ghobadi, Armin, Jacobson, Caron A, Miklos, David B, Lekakis, Lazaros J, Oluwole, Olalekan O, Lin, Yi, Braunschweig, Ira, Hill, Brian T, Timmerman, John M, Deol, Abhinav, Reagan, Patrick M, Stiff, Patrick, Flinn, Ian W, Farooq, Umar, Goy, Andre, McSweeney, Peter A, Munoz, Javier, Siddiqi, Tanya, Chavez, Julio C, Herrera, Alex F, Bartlett, Nancy L, Wiezorek, Jeffrey S, Navale, Lynn, Xue, Allen, Jiang, Yizhou, Bot, Adrian, Rossi, John M, Kim, Jenny J, Go, William Y, Neelapu, Sattva S

“…Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study,…”
Get full text

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience by O'Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C.

“…We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naïve (TN) older patients (≥65 years of age)…”
Get full text

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia by Stein, Eytan M., DiNardo, Courtney D., Pollyea, Daniel A., Fathi, Amir T., Roboz, Gail J., Altman, Jessica K., Stone, Richard M., DeAngelo, Daniel J., Levine, Ross L., Flinn, Ian W., Kantarjian, Hagop M., Collins, Robert, Patel, Manish R., Frankel, Arthur E., Stein, Anthony, Sekeres, Mikkael A., Swords, Ronan T., Medeiros, Bruno C., Willekens, Christophe, Vyas, Paresh, Tosolini, Alessandra, Xu, Qiang, Knight, Robert D., Yen, Katharine E., Agresta, Sam, de Botton, Stephane, Tallman, Martin S.

“…Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically…”
Get full text

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma by Leonard, John P, Trneny, Marek, Izutsu, Koji, Fowler, Nathan H, Hong, Xiaonan, Zhu, Jun, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana, Nowakowski, Grzegorz S, Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian W, Moreira, Claudia, Cabeçadas, José, Liu, David, Kalambakas, Stacey, Fustier, Pierre, Wu, Chengqing, Gribben, John G

“…Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly…”
Get full text

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL by Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone J., Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P., Cashen, Amanda F., Weaver, David T., Kelly, Virginia M., Turnbull, Barry, Stilgenbauer, Stephan

“…Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ and γ (PI3K-δ,γ) being developed for treatment of hematologic…”
Get full text

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial by Moreno, Carol, Greil, Richard, Demirkan, Fatih, Tedeschi, Alessandra, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Novak, Jan, Strugov, Vladimir, Gill, Devinder, Gribben, John G, Kwei, Kevin, Dai, Sandra, Hsu, Emily, Dean, James P, Flinn, Ian W

“…iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line…”
Get full text

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study by Flinn, Ian W., van der Jagt, Richard, Kahl, Brad S., Wood, Peter, Hawkins, Tim E., MacDonald, David, Hertzberg, Mark, Kwan, Yiu-Lam, Simpson, David, Craig, Michael, Kolibaba, Kathryn, Issa, Samar, Clementi, Regina, Hallman, Doreen M., Munteanu, Mihaela, Chen, Ling, Burke, John M.

“…This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety of bendamustine plus rituximab (BR) vs a standard…”
Get full text

The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival by Danilov, Alexey V, Flinn, Ian W, Davids, Matthew S, Gregory, Beth, Bentur, Ohad, Sidransky, David, Brown, Jennifer R

Get full text

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial by Kantarjian, Hagop M, Prof, Hochhaus, Andreas, Prof, Saglio, Giuseppe, Prof, De Souza, Carmino, Prof, Flinn, Ian W, MD, Stenke, Leif, MD, Goh, Yeow-Tee, MD, Rosti, Gianantonio, Prof, Nakamae, Hirohisa, MD, Gallagher, Neil J, MD, Hoenekopp, Albert, MD, Blakesley, Rick E, PhD, Larson, Richard A, Prof, Hughes, Timothy P, Prof

“…Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid…”
Get full text

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Woyach, Jennifer A., Awan, Farrukh, Flinn, Ian W., Berdeja, Jesus G., Wiley, Elizabeth, Mansoor, Sharmeen, Huang, Ying, Lozanski, Gerard, Foster, Paul A., Byrd, John C.

“…CD19 is ubiquitously expressed on chronic lymphocytic leukemia (CLL) cells and is therefore an attractive candidate for antibody targeting. XmAb5574 (aka…”
Get full text

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial by Jones, Jeffrey A, Dr, Robak, Tadeusz, Prof, Brown, Jennifer R, MD, Awan, Farrukh T, MD, Badoux, Xavier, MBBS, Coutre, Steven, Prof, Loscertales, Javier, MD, Taylor, Kerry, MBBS, Vandenberghe, Elisabeth, Prof, Wach, Malgorzata, MD, Wagner-Johnston, Nina, Prof, Ysebaert, Loic, MD, Dreiling, Lyndah, MD, Dubowy, Ronald, MD, Xing, Guan, PhD, Flinn, Ian W, MD, Owen, Carolyn, MD

“…Summary Background Idelalisib, a selective inhibitor of PI3Kδ, is approved for the treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) in…”
Get full text

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma by Berdeja, Jesus G, Hart, Lowell L, Mace, Joseph R, Arrowsmith, Edward R, Essell, James H, Owera, Rami S, Hainsworth, John D, Flinn, Ian W

“…The purpose of this study was to assess the safety and efficacy of the combination of panobinostat and carfilzomib in patients with relapsed/refractory…”
Get full text

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study by Salles, Gilles, Schuster, Stephen J, de Vos, Sven, Wagner-Johnston, Nina D, Viardot, Andreas, Blum, Kristie A, Flowers, Christopher R, Jurczak, Wojciech J, Flinn, Ian W, Kahl, Brad S, Martin, Peter, Kim, Yeonhee, Shreay, Sanatan, Will, Matthias, Sorensen, Bess, Breuleux, Madlaina, Zinzani, Pier Luigi, Gopal, Ajay K

Get full text

Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 by FLINN, Ian W, NEUBERG, Donna S, TALLMAN, Martin S, GREVER, Michael R, DEWALD, Gordon W, BENNETT, John M, PAIETTA, Elisabeth M, HUSSEIN, Mohamad A, APPELBAUM, Frederick R, LARSON, Richard A, MOORE, Dennis F

“…The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic leukemia (CLL). However, it may be…”
Get full text

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies by Xu, Linlin, Shadman, Mazyar, Flinn, Ian W, Levy, Moshe Y, Porter, Ryan, Burke, John M, Zafar, Syed F, Cultrera, Jennifer L, Misleh, Jamal, Kingsley, Edwin C, Yimer, Habte A, Freeman, Benjamin, Chaudhry, Arvind, Tumula, Praveen K, Gandhi, Mitul D, Crescenzo, Rocco, By, Kunthel, Cohen, Aileen, Chen, Dih-Yih, Idoine, Adam, Manda, Sudhir, Sharman, Jeff P, Ramakrishnan, Vanitha

Get full text

Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997 by GREVER, Michael R, LUCAS, David M, PAIETTA, Elisabeth, JELINEK, Diane F, GRIBBEN, John G, BYRD, John C, DEWALD, Gordon W, NEUBERG, Donna S, REED, John C, KITADA, Shinichi, FLINN, Ian W, TALLMAN, Martin S, APPELBAUM, Frederick R, LARSON, Richard A

“…Genomic features including unmutated immunoglobulin variable region heavy chain (IgVH) genes, del(11q22.3), del(17p13.1), and p53 mutations have been reported…”
Get full text

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia by Byrd, John C., Pagel, John M., Awan, Farrukh T., Forero, Andres, Flinn, Ian W., Deauna-Limayo, Delva P., Spurgeon, Stephen E., Andritsos, Leslie A., Gopal, Ajay K., Leonard, John P., Eisenfeld, Amy J., Bannink, Jeannette E., Stromatt, Scott C., Furman, Richard R.

“…Otlertuzumab is a novel humanized anti-CD37 protein therapeutic. This study evaluated the safety of otlertuzumab administered intravenously to patients with…”
Get full text

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma by Tedeschi, Alessandra, Greil, Richard, Demirkan, Fatih, Robak, Tadeusz, Moreno, Carol, Barr, Paul M, Anz, Bertrand, Simpson, David, Gaidano, Gianluca, Bairey, Osnat, Stevens, Don, Gill, Devinder, Flinn, Ian W, Kipps, Thomas J, Burger, Jan A, Lin, Jennifer, Webb, Thomas, Fedorov, Viktor, Styles, Lori, Gribben, John G

Get full text

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma by WITZIG, Thomas E, FLINN, Ian W, WHITE, Christine A, GORDON, Leo I, EMMANOUILIDES, Christos, CZUCZMAN, Myron S, SALEH, Mansoor N, CRIPE, Larry, WISEMAN, Gregory, OLEJNIK, Teresa, MULTANI, Pratik S

“…Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the…”
Get full text

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy by Lamanna, Nicole, Tam, Constantine S., Woyach, Jennifer A., Alencar, Alvaro J., Palomba, M. Lia, Zinzani, Pier Luigi, Flinn, Ian W., Fakhri, Bita, Cohen, Jonathon B., Kontos, Arrin, Konig, Heiko, Ruppert, Amy S., Chatterjee, Anindya, Sizelove, Richard, Compte, Livia, Tsai, Donald E., Jurczak, Wojciech

“…Clinical bleeding events are reported here from 773 patients with B‐cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study…”
Get full text